How Well Can You Actually Predict Which Non–Muscle-Invasive Bladder Cancer Patients Will Progress?

This publication has 10 references indexed in Scilit:

• The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables
  European Urology, 2011
• EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
  European Urology, 2011
• External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer
  World Journal of Urology, 2010
• Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines
  BJU International, 2010
• Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer
  European Urology, 2010
• Expression Signature of E2F1 and Its Associated Genes Predict Superficial to Invasive Progression of Bladder Tumors
  Journal of Clinical Oncology, 2010
• Role of biomarkers to predict outcomes and response to therapy
  Urologic Oncology: Seminars and Original Investigations, 2010
• Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
  Journal of Urology, 2009
• Combining a molecular profile with a clinical and pathological profile: Biostatistical considerations
  Scandinavian Journal of Urology and Nephrology, 2008
• Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
  European Urology, 2006